Literature DB >> 33527128

Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.

Randy M Stalter1,2, Jared M Baeten1,2,3, Deborah Donnell1,4, Matthew A Spinelli5, David V Glidden5, Warren C Rodrigues6, Guohong Wang6, Michael Vincent6, Nelly Mugo1,7, Andrew Mujugira1,8, Mark Marzinke9, Craig Hendrix9, Monica Gandhi5.   

Abstract

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  PrEP; ELISA; HIV prevention; immunoassay; urine

Year:  2021        PMID： 33527128      PMCID： PMC7850546          DOI： 10.1093/cid/ciaa785

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Authors:  H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas
Journal:  HIV Med       Date:  2017-04-26       Impact factor: 3.180

2.  Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.

Authors:  Travis Hunt; Linden Lalley-Chareczko; Giffin Daughtridge; Meghan Swyryn; Helen Koenig
Journal:  AIDS Care       Date:  2019-03-01

3.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.

Authors:  Richard E Haaland; Amy Martin; Tamee Livermont; Jeffrey Fountain; Chuong Dinh; Angela Holder; Lindsey D Lupo; LaShonda Hall; Christopher Conway-Washington; Colleen F Kelley
Journal:  J Acquir Immune Defic Syndr       Date:  2019-11-01       Impact factor: 3.731

Review 5.  Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.

Authors:  Jessica E Haberer
Journal:  Curr Opin HIV AIDS       Date:  2016-01       Impact factor: 4.283

6.  Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.

Authors:  Monica Gandhi; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Jared M Baeten; Oraphan Siriprakaisil; Virat Klinbuayaem; Warren C Rodrigues; Guohong Wang; Michael Vincent; Tim R Cressey; Paul K Drain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

7.  Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).

Authors:  Paul K Drain; Rachel W Kubiak; Oraphan Siriprakaisil; Virat Klinbuayaem; Justice Quame-Amaglo; Pra-Ornsuda Sukrakanchana; Suriyan Tanasri; Pimpinun Punyati; Wasna Sirirungsi; Ratchada Cressey; Peter Bacchetti; Hideaki Okochi; Jared M Baeten; Monica Gandhi; Tim R Cressey
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

8.  Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.

Authors:  Monica Gandhi; Guohong Wang; Roger King; Warren C Rodrigues; Michael Vincent; David V Glidden; Tim R Cressey; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Oraphan Siriprakaisil; Virat Klinbuayaem; Nelly R Mugo; Kenneth Ngure; Paul K Drain; Jared M Baeten
Journal:  AIDS       Date:  2020-02-01       Impact factor: 4.632

9.  HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Authors:  Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

Review 10.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.

Authors:  Virginia A Fonner; Sarah L Dalglish; Caitlin E Kennedy; Rachel Baggaley; Kevin R O'Reilly; Florence M Koechlin; Michelle Rodolph; Ioannis Hodges-Mameletzis; Robert M Grant
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177
View more
  4 in total

1.  Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.

Authors:  Ariana Wendy Keel Katz; Iván C Balán; Krishnaveni Reddy; Juliane Etima; Kubashni Weber; Thelma Tauya; Millicent Atujuna; Rachel Scheckter; Kenneth Ngure; Lydia Soto-Torres; Nyaradzo Mgodi; Thesla Palanee-Phillips; Jared M Baeten; Ariane van der Straten
Journal:  AIDS Behav       Date:  2022-05-10

2.  Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.

Authors:  Lauren Jennings; Tracy Kellermann; Matthew Spinelli; Zukiswa Nkantsu; Dolphina Cogill; Marije van Schalkwyk; Eric Decloedt; Gert van Zyl; Catherine Orrell; Monica Gandhi
Journal:  AIDS Res Hum Retroviruses       Date:  2021-12-29       Impact factor: 1.723

3.  Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA.

Authors:  Lorraine T Dean; Hsien-Yen Chang; William C Goedel; Philip A Chan; Jalpa A Doshi; Amy S Nunn
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

4.  Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.

Authors:  Ashley R Bardon; Jienchi Dorward; Yukteshwar Sookrajh; Fathima Sayed; Justice Quame-Amaglo; Cheryl Pillay; Erika Feutz; Hope Ngobese; Jane M Simoni; Monisha Sharma; Tim R Cressey; Monica Gandhi; Richard Lessells; Pravi Moodley; Nivashnee Naicker; Kogieleum Naidoo; Katherine Thomas; Connie Celum; Salim Abdool Karim; Nigel Garrett; Paul K Drain
Journal:  BMJ Open       Date:  2021-10-05       Impact factor: 3.006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.